[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-activation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-activation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100640436","change-in-platelet-lipid-metabolism-and-procoagulant-phenotype-induced-by-cardiopulmonary-bypass-impact-on-postoperative-inflammatory-response-and-bleeding-complications-during-cardiac-surgery-100640436",false,"NCT07630987","Change in Platelet Lipid Metabolism and Procoagulant Phenotype Induced by Cardiopulmonary Bypass. Impact on Postoperative Inflammatory Response and Bleeding Complications During Cardiac Surgery.","PLACARD","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old) suffering from coronary disease and\u002For severe valvular dysfunction (mitral or aortic) undergoing elective coronary angiography or cardiac surgery with cardiopulmonary bypass.\n\nExclusion Criteria:\n\n* Uninterrupted preoperative dual antiplatelet therapy\n* Active chronic inflammatory disease\n* Recent chemotherapy or immunotherapy (\\\u003C 3 months)\n* Active solid malignancy\n* History of hematologic malignancy\n* Hemophilia or other coagulopathy\n* History of thrombocytopenia (\\\u003C 100,000 platelets\u002Fmm³)\n* Recent administration of thrombopoietin receptor agonist or immunoglobulins\n* History of thrombopathy, thrombocytosis, or myeloproliferative syndrome\n* History of heparin-induced thrombocytopenia (HIT)\n* Cirrhosis or hepatic fibrosis (with or without hypersplenism)\n* History of splenectomy, regardless of initial indication\n* History of systemic autoimmune disease (e.g., systemic lupus erythematosus, scleroderma, antiphospholipid syndrome, systemic vasculitis)\n* Recent major surgery (\\\u003C 3 months)\n* Severe renal insufficiency (eGFR ≤ 30 mL\u002Fmin\u002Fm²) with or without dialysis\n* Recent or chronic corticosteroid therapy\n* Recent acute coronary syndrome, STEMI type (\\\u003C 3 months)\n* Urgent surgery or procedure\n* Preoperative hemodynamic instability","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","The PLACARD research project aims to investigate the impact of CPB-induced platelet modifications during cardiac surgery on the post-operative inflammatory response and bleeding complications. Our objectives are to study the impact of CPB on the formation of procoagulant platelets, to assess changes in platelet lipid profile and bioenergetics before, during and after cardiac surgery, and to connect the ex-vivo observations to post-operative clinical and biological parameters of these patients during their stay in cardiovascular intensive care unit.",[26,27,28],"Cardiac Surgery","Cardiopulmonary Bypass","Platelet Activation",[30,31,32,33],"Procoagulant platelets","Platelet lipidomics","Postoperative inflammation","Postoperative bleeding","NOT_YET_RECRUITING","2026-06-02",{"date":37,"type":38},"2026-06-05","ACTUAL",{"date":40,"type":20},"2026-05-15",{"date":42,"type":20},"2030-01",{"name":44,"class":45},"Université Catholique de Louvain","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100549313","coagulation-factors-alterations-in-patients-undergoing-complex-thoraco-abdominal-aortic-aneurysm-repair-100549313","NCT06432387","Coagulation Factors Alterations in Patients Undergoing Complex Thoraco-abdominal Aortic Aneurysm Repair","Coagulation Factors Alterations in Patients Undergoing Complex Thoraco-abdominal Aortic Aneurysm Repair (CoFA-TAAA); a Prospective Observational Study","CoFA-TAAA","Inclusion Criteria:\n\n* Consecutive patients undergoing complex thoraco-abdominal aortic aneurysm repair in University Hospital of Larissa, after informed consent will be included.\n\nExclusion Criteria:\n\n* Refuse to participate\n* Prior surgery within 3 months\n* ASA PS \\> 3\n* Known medical history of thrombophilia or functional platelet dysfunction",{"count":56,"type":20},58,"OBSERVATIONAL","This study will evaluate the impact of complex thoraco-abdominal aortic aneurysm repair in coagulation during the immediate postoperative period in patients undergoing omplex thoraco-abdominal aortic aneurysm repair.",[60,61,28],"Thoraco-abdominal Aortic Aneurysm Repair","Coagulation Factors Alterations","RECRUITING","2026-05-03",{"date":65,"type":38},"2026-05-07",{"date":67,"type":38},"2024-12-31",{"date":69,"type":20},"2027-07-20",{"name":71,"class":45},"University of Thessaly",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":91,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100518650","characterization-and-quantification-of-plateletleukocyte-aggregates-in-patients-with-suspected-heparin-induced-thrombocytopenia-100518650","NCT06033300","Characterization and Quantification of Platelet\u002FLeukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia","HITSTREAM","Inclusion Criteria:\n\n* Age \\> 18 years\n* Any adult patient suspected of having HIT, with a positive anti-PF4\u002FH antibody test\n* Patient signed consent to study participation\n* Patient with social security coverage\n\nExclusion Criteria:\n\n* All adult patients with suspected HIT and negative anti-PF4\u002FH antibody test.\n* Protected adults (guardianship, under curators) or deprived of liberty",{"count":81,"type":20},200,[23],"The investigators would like to analyze platelet\u002Fleukoplak activation, quantify and morphologically characterize these aggregates using in vitro analysis, directly on whole blood from adult patients with suspected HIT. This would enable to better describe the in vivo pathophysiology of the HIT-suspect patient, and eliminate the need for platelet donors to perform the usual confirmatory techniques, whose inter- and intra-individual variability is very high. What's more, the SRA test, evaluated as the reference test, requires the use of radioisotopes and is therefore only carried out in a few biological expertise centers, resulting in a very long delay in the delivery of results. It should also be noted that, in practice, HÉPARINE is immediately stopped in patients with suspected HIT, and they are put on an expensive anticoagulant (DANAPAROIDE SODIQUE or ARGATROBAN) in curative doses until the results of the confirmatory tests are back. In this serious, life-threatening condition, it is essential to have a sensitive, specific test to confirm HIT as quickly as possible. Each patient with suspected HIT (rapid \\>30% reduction in platelet count after initiation of heparin therapy) should have 4 tubes of 3.2% citrated whole blood (2.7ml) collected at the time of suspected HIT (D0) and before any therapeutic switch (or 24 h max after switch). A new sample (4 citrated tubes) will be taken at D4, D7 and D14 during hospitalization, in patients who test positive for anti-PF4\u002FH Ac. All patients with suspected HIT will follow the standard diagnostic pathway, i.e. a screening test (immunological test for anti-PF4\u002Fheparin antibodies, total Ig, ACL TOP, Werfen) followed by a confirmatory test (platelet aggregation on TA-8V, STAGO and\u002For SRA). Doppler ultrasonography of the lower limbs will be performed in HIT-suspect patients with a positive anti-PF4\u002FH antibody test, as currently performed as part of routine care.",[85,86,28,87,88,89,78,90],"Heparin-induced Thrombocytopenia","HIT","Platelets","Leukocytes","Platelet\u002FLeukocyte Aggregates","Flow Cytometry",[85],"2025-05-21",{"date":94,"type":38},"2025-05-25",{"date":96,"type":38},"2023-04-17",{"date":98,"type":20},"2026-04",{"name":100,"class":45},"Centre Hospitalier Universitaire, Amiens"]